FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma. PMID 39476124 · Blood · 2025-Jan-09 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies. PMID 39316653 · Blood · 2025-Jan-09 The record describes a Phase III randomized trial with a time-to-event efficacy endpoint (EFS), but the provided abstract does not establish a drug-containing intervention as required for eligibility. The intervention described is treatment stratification based on risk classification, not the administration of a specific drug. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk. PMID 39225259 · N Engl J Med · 2025-Jan-09 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease. PMID 39780249 · Alzheimers Res Ther · 2025-Jan-08 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Comparative study between high and low dose methylene blue infusion in septic cancer patients: a randomized, blinded, controlled study. PMID 39780053 · BMC Anesthesiol · 2025-Jan-08 The trial is randomized and includes cancer patients, but the drug intervention (methylene blue) is for managing septic shock, not for treating the cancer. Therefore, it does not meet the criterion of a drug-containing intervention for oncology. The primary endpoint is also not a standard oncology time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Anti-PD-1 and anti-PD-L1 antibodies for glioma. PMID 39777725 · Cochrane Database Syst Rev · 2025-Jan-08 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Patient experience with eosinophilic esophagitis symptoms and impacts on daily life based on in-trial qualitative interviews. PMID 39777591 · J Patient Rep Outcomes · 2025-Jan-08 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Statistical methods in the analysis of multicentre HIV randomized controlled trials in the African region: a scoping review. PMID 39773382 · BMC Med Res Methodol · 2025-Jan-08 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effect of add-on naldemedine treatment in patients with cancer and opioid-induced constipation insufficiently responding to magnesium oxide: a pooled, subgroup analysis of two randomized controlled trials. PMID 39354673 · Jpn J Clin Oncol · 2025-Jan-08 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Protocol digest of a phase III randomized trial of gross total resection versus possible resection of fluid-attenuated inversion recovery-hyperintense lesion on MRI for newly diagnosed supratentorial glioblastoma: JCOG2209 (FLAMINGO). PMID 39292165 · Jpn J Clin Oncol · 2025-Jan-08 The record is a protocol for a phase III randomized trial with a primary OS endpoint, but it lacks formal results and describes a surgical intervention, not a drug-containing one. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Challenges in multinational rare disease clinical studies during COVID-19: regulatory assessment of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease. PMID 39775064 · J Neurol · 2025-Jan-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Thromboembolic Events in the Hemodialysis Setting: Understanding Risk Profiles and Cumulative Incidences to Inform Clinical Trial Design. PMID 39719420 · J Am Heart Assoc · 2025-Jan-07 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Fatigue After Stroke Educational Recovery Program: A Prospective, Phase III, Randomized Controlled Trial. PMID 39719403 · J Am Heart Assoc · 2025-Jan-07 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Intravenous Lidocaine for Gut Function Recovery in Colonic Surgery: A Randomized Clinical Trial. PMID 39602290 · JAMA · 2025-Jan-07 The study is a randomized trial of a drug (lidocaine) in patients undergoing colon resection, but it is not an oncology trial focused on cancer outcomes. The primary endpoint is a composite measure of gut function recovery (GI-3), not a time-to-event oncology endpoint like OS, PFS, or DFS. While some patients had malignant disease, the trial is not primarily designed or powered for oncology efficacy. Therefore, it does not meet the inclusion criteria for the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Central ligation or partial preservation of the right gastric artery does not seem to affect conduit or anastomotic perfusion during robot-assisted resection of gastroesophageal junction cancer: a randomized clinical trial. PMID 39558692 · Dis Esophagus · 2025-Jan-07 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| First Measurement: Proactive Immune Cell Sparing in Radiation Therapy. PMID 39830271 · medRxiv · 2025-Jan-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Effect of different intraoperative blood pressure regulation levels on postoperative myocardial injury in patients undergoing radical mastectomy for breast cancer after receiving neoadjuvant chemotherapy: a study protocol for a randomised controlled trial. PMID 39762100 · BMJ Open · 2025-Jan-06 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Home high-flow therapy during recovery from severe chronic obstructive pulmonary disease (COPD) exacerbation: a mixed-methods feasibility randomised control trial. PMID 39762067 · BMJ Open Respir Res · 2025-Jan-06 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer. PMID 39513948 · Clin Cancer Res · 2025-Jan-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer Surgery. PMID 39187984 · Cancer Prev Res (Phila) · 2025-Jan-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Effects of hydrolyzed yeast on weanling pig growth performance, fecal dry matter, and stress-related blood antioxidant criteria. PMID 41002176 · J Anim Sci · 2025-Jan-04 仅见动物/临床前证据,不是人体临床试验。 |
H
|
仅历史库存 | excludednon_human | pending 0 Figure · 0 Panel · risk - |
| Supplemental effects of acidifier and encapsulated butyrate solely and combined in high canola meal diets for nursery pigs. PMID 40233213 · J Anim Sci · 2025-Jan-04 仅见动物/临床前证据,不是人体临床试验。 |
H
|
仅历史库存 | excludednon_human | pending 0 Figure · 0 Panel · risk - |
| Supporting endocrine therapy adherence in women with breast cancer: findings from the ROSETA pilot fractional factorial randomized trial. PMID 39887069 · Ann Behav Med · 2025-Jan-04 The study is a pilot/feasibility randomized trial for an intervention to improve endocrine therapy adherence, not a Phase III definitive efficacy trial. It does not report time-to-event efficacy outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of behavior change techniques to address barriers to follow-up colonoscopy: results from an online survey and randomized factorial experiment. PMID 39739614 · Ann Behav Med · 2025-Jan-04 The study is an online randomized factorial experiment testing behavior change techniques to increase colonoscopy follow-up intentions. While it is human, oncology-related, and randomized, it lacks a drug-containing intervention and does not report a time-to-event efficacy endpoint. It is therefore excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. PMID 39706209 · Lancet · 2025-Jan-04 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Abdominal visceral and subcutaneous adipose tissue associations with postmenopausal breast cancer incidence. PMID 39847539 · JNCI Cancer Spectr · 2025-Jan-03 The record describes an observational cohort study, not a randomized trial of a drug intervention. Despite publication tags, the methods and abstract do not indicate a randomized trial of a therapeutic agent for cancer treatment or prevention with a time-to-event efficacy endpoint. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial. PMID 39579142 · JNCI Cancer Spectr · 2025-Jan-03 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 1 Figure · 1 Panel · risk unclear |
| Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy. PMID 39556192 · J Antimicrob Chemother · 2025-Jan-03 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Nelonemdaz and Patients With Acute Ischemic Stroke and Mechanical Reperfusion: The RODIN Randomized Clinical Trial. PMID 39874036 · JAMA Netw Open · 2025-Jan-02 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring. PMID 39841472 · JAMA Netw Open · 2025-Jan-02 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 4 Figure · 18 Panel · risk visible |
| Androgen Receptor Pathway Inhibitor Therapy for Advanced Prostate Cancer: Secondary Analysis of a Randomized Clinical Trial. PMID 39804646 · JAMA Netw Open · 2025-Jan-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Primary Mediastinal Ewing's Sarcoma: Post Hoc Analysis from Two International Multicenter Prospective Randomized Trials. PMID 39796745 · Cancers (Basel) · 2025-Jan-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Value of ctDNA in surveillance of adjuvant chemosensitivity and regimen adjustment in stage III colon cancer: a protocol for phase II multicentre randomised controlled trial (REVISE trial). PMID 39753246 · BMJ Open · 2025-Jan-02 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging. PMID 39752157 · JAMA Netw Open · 2025-Jan-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Reduction of pain and functional disability over time in patients treated with zavegepant: a post-hoc analysis of the BHV3500-301 phase 3 randomized controlled trial. PMID 39748312 · J Headache Pain · 2025-Jan-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis. PMID 39321347 · Blood · 2025-Jan-02 The record describes a secondary analysis of two randomized trials. The original trials are not explicitly identified as Phase III/IIIb or Phase II/III in the provided metadata or abstract. The analysis itself is a pooled secondary analysis, not the primary report of a definitive Phase III trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. PMID 39282902 · N Engl J Med · 2025-Jan-02 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 3 Figure · 4 Panel · risk unclear |
| Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. PMID 39282897 · N Engl J Med · 2025-Jan-02 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 2 Figure · 5 Panel · risk unclear |
| Asundexian versus Apixaban in Patients with Atrial Fibrillation. PMID 39225267 · N Engl J Med · 2025-Jan-02 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. PMID 39213194 · N Engl J Med · 2025-Jan-02 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Role of precise management model in the maintenance of central venous indwelling catheters for cancer patients. PMID 40377613 · Indian J Cancer · 2025-Jan-01 The study is a randomized trial on catheter maintenance in cancer patients, but it does not meet the core eligibility criteria: it is not a drug intervention trial, does not report a time-to-event efficacy endpoint (like OS, PFS, etc.), and lacks a specified Phase III/IIIb or definitive phase. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Positron emission tomography versus computed tomography -guided intracavitary brachytherapy for locally advanced cervical cancer: A prospective randomized study. PMID 40214368 · J Cancer Res Ther · 2025-Jan-01 The trial is randomized and reports time-to-event efficacy endpoints (OS, LC) in human oncology patients. However, the randomized intervention is a radiotherapy planning/guidance technique (PET-CT vs. CT), not a drug-containing intervention versus control. Cisplatin is given concurrently to both arms as part of the standard chemoradiotherapy backbone, not as the variable under investigation. Therefore, it does not meet the requirement for a drug-containing intervention as the primary randomized comparison. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Symptomatic Improvement in Adults and Adolescents With Eosinophilic Esophagitis Requires Higher Systemic Dupilumab Exposure Than Histologic Response. PMID 39853721 · Clin Transl Gastroenterol · 2025-Jan-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Empirical use of growth hormone in IVF is useless: the largest randomized controlled trial. PMID 39673334 · Hum Reprod · 2025-Jan-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Biochemical response to neoadjuvant androgen deprivation therapy before radiation therapy and the risk of death in patients with unfavorable-risk prostate cancer: A secondary analysis of a randomized clinical trial. PMID 39632606 · Cancer · 2025-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials. PMID 39602111 · JAMA Dermatol · 2025-Jan-01 The study is a randomized, phase 3 trial of a drug (deucravacitinib) in psoriasis, but it is not an oncology study. The primary efficacy endpoints are clinical response rates (PASI 75/90, sPGA 0/1), not time-to-event outcomes like OS, PFS, or DFS. The inclusion criteria require an oncology (malignant neoplasm) study with a time-to-event primary/key secondary efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. PMID 39570620 · JAMA Oncol · 2025-Jan-01 The trial is a Phase 1b study with a primary endpoint of pharmacokinetics and secondary endpoints of safety and response rates. It does not meet the required Phase III/IIIb or Phase II/III criteria, and lacks a time-to-event efficacy endpoint such as OS or PFS. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases: Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial. PMID 39570583 · JAMA Oncol · 2025-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Protocol for the Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Studies. PMID 39560771 · Pediatr Crit Care Med · 2025-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease. PMID 39556389 · JAMA Neurol · 2025-Jan-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |